EUVIMEDEUVIMED entdecken
Crossref

AQbD‐Optimized Chiral HPLC for Ruxolitinib Purity Control

Roula Bayram, Asmaa Saleh, Jawaher Abdullah Alamoudi, Reham Ali, Ahmed M. Ibrahim

Chirality · 2026-12 · 38 (12)

DOI: 10.1002/chir.70164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chirality, online erschienen am 18.11.2026. Verfasst von Roula Bayram und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Princess Nourah Bint Abdulrahman University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ruxolitinib phosphate (RUX) is a potent Janus kinase (JAK) inhibitor whose strict stereoselective pharmacodynamics necessitate rigorous enantiomeric purity control during pharmaceutical manufacturing. Although foundational enantioseparations of RUX have been previously reported, there remains a critical lack of robust quantitative assays capable of trace‐level impurity monitoring. To address this gap, the primary novelty of this study lies in the establishment of a rigorously validated normal‐phase high‐performance liquid chromatography (NP‐HPLC) method specifically tailored for the trace‐level determination of the ( S )‐enantiomer. Engineered via an analytical quality by design (AQbD) framework, the methodology sequentially deployed fractional factorial design (FFD) and face‐centered central composite design (FCCD). Through this approach, key thermodynamic and kinetic parameters were mathematically modeled to delineate a resilient method operable design region (MODR). Optimal stereoselective discrimination was achieved on a CHIRALCEL OD‐H stationary phase utilizing an isocratic n‐hexane/ethanol (92:8, v/v) eluent, yielding baseline enantiomeric resolution (R s ≈ 3.0) within a run time (RT) of 20 min. Methodological reliability was comprehensively verified utilizing the total error approach, demonstrating trueness, precision, and sensitive quantitation limits of 0.50 μg mL −1 for ( S )‐enantiomer. Finally, method robustness against matrix interference was empirically confirmed via standard addition on commercial formulations, demonstrating its fit‐for‐purpose utility for routine quality control.

Förderung

  • Princess Nourah Bint Abdulrahman University

Zitieren

APA

Bayram, R., Saleh, A., Alamoudi, J. A., Ali, R., & Ibrahim, A. M. (2026). AQbD‐Optimized Chiral HPLC for Ruxolitinib Purity Control. Chirality, 38(12). https://doi.org/10.1002/chir.70164

Vancouver

Bayram R, Saleh A, Alamoudi JA, Ali R, Ibrahim AM. AQbD‐Optimized Chiral HPLC for Ruxolitinib Purity Control. Chirality. 2026;38(12). doi:10.1002/chir.70164

BibTeX
@article{Bayram2026,
  author = {Bayram, Roula and Saleh, Asmaa and Alamoudi, Jawaher Abdullah and Ali, Reham and Ibrahim, Ahmed M.},
  title = {AQbD‐Optimized Chiral HPLC for Ruxolitinib Purity Control},
  journal = {Chirality},
  year = {2026},
  volume = {38},
  number = {12},
  doi = {10.1002/chir.70164}
}
Kostenlos starten →